Comparative Pharmacology
Head-to-head clinical analysis: FUNDUSCEIN 25 versus KINEVAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUNDUSCEIN 25 versus KINEVAC.
FUNDUSCEIN-25 vs KINEVAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorescein sodium absorbs blue light (465–490 nm) and emits yellow-green fluorescence (520–530 nm), allowing visualization of retinal and choroidal vasculature. It binds to serum proteins and leaks from abnormal blood vessels, highlighting areas of neovascularization or edema.
KINEVAC (sincalide) is a synthetic analog of cholecystokinin (CCK) that stimulates gallbladder contraction and pancreatic secretion by binding to CCK-1 receptors on gallbladder smooth muscle and pancreatic acinar cells, leading to release of bile and pancreatic enzymes.
0.5 mL of FUNDUSCEIN-25 (25 mg/mL) administered intravenously as a single bolus injection over 5-10 seconds.
KINEVAC (sincalide) is administered as an IV injection or infusion. For gallbladder contraction/cholecystography: 0.02 mcg/kg IV over 30-60 seconds; may repeat once after 15 minutes if inadequate response. For pancreatic function testing: 0.02 mcg/kg IV over 30-60 seconds followed by secretin stimulation.
None Documented
None Documented
Terminal elimination half-life is approximately 26 minutes in adults (range 20–30 minutes). Clinical context: Rapid clearance allows repeated injections within 30–60 minutes if needed.
Terminal elimination half-life is 22 hours (range 15-30 hours) in patients with normal renal function. Clinically, this supports once-daily dosing.
Primarily renal elimination of unchanged fluorescein and its glucuronide conjugate (80% within 24 hours). Biliary/fecal excretion accounts for <5%.
Biliary/fecal: >90% as unchanged drug; renal: <5% as metabolites.
Category C
Category C
Diagnostic Agent
Diagnostic Agent, Secretin Analog